However, the numerical inferiority of BTK inhibition in preventing gadolinium-enhancing MRI lesions in participants with relapsing MS4,45 suggests a putative disadvantage of BTK inhibition compared to teriflunomide in suppressing the acute focal inflammatory component of MS. Here, BTK is linked to myeloid sarcoma.